89bio, Inc. (ETNB), a clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, announced Wednesday positive topline data from the Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with nonalcoholic steatohepatitis or NASH.
from RTT - Before the Bell https://ift.tt/DXgqKBA
via IFTTT
No comments:
Post a Comment